Pyc Therapeutics
Clinical trials sponsored by Pyc Therapeutics, explained in plain language.
-
First human trial for genetic eye disease treatment begins
Disease control Recruiting nowThis early-stage study is testing the safety of a new eye injection called PYC-001 in adults with a specific genetic condition that causes progressive vision loss (OPA1-related optic atrophy). About 21 participants in the UK and Australia will receive different doses and schedule…
Phase: PHASE1, PHASE2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
First human test for potential genetic kidney disease treatment begins
Disease control Recruiting nowThis is the first study in people to test the safety of a new drug called PYC-003. It aims to see how the body handles the drug and if it is safe for healthy adults and for adults with a specific genetic form of polycystic kidney disease (ADPKD). The study will give the drug as a…
Phase: PHASE1 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Mar 27, 2026 12:37 UTC
-
Experimental eye injections aim to halt rare genetic blindness
Disease control Recruiting nowThis study is testing the safety and effectiveness of repeat injections of an experimental drug, VP-001, into the eye. It is for adults with a rare, inherited form of vision loss called PRPF31 mutation-associated retinal dystrophy. The goal is to see if the injections can help co…
Phase: PHASE1, PHASE2 • Sponsor: PYC Therapeutics • Aim: Disease control
Last updated Mar 19, 2026 14:55 UTC